Alnair Therapeutics
PrivateLast Round
Seed
Feb 13, 2026
Total Funding Raised
$1.76M
Company Overview
Alnair Therapeutics is a biotechnology company developing a first-in-class drug delivery technology that leverages the features of cancer metabolism to enhance the targeting and penetration of drugs directly to cancer cells.
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alnair Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Alnair Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Feb 13, 2026 | ||||
| Pre Seed | Jun 30, 2023 | ||||
| Accelerator | Jun 2, 2023 | ||||
| Grant | Jan 30, 2023 |
Alnair Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gaingels | Pre Seed |
| George Shultz Innovation Fund | Grant |
| Portal Innovations | Pre Seed |
| Polsky Center for Entrepreneurship and Innovation at the University of Chicago | Accelerator |
| OCA Ventures | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 13, 2026
$10M raised in Seed round.
- Jun 30, 2023
$1M raised from Gaingels, OCA Ventures, and Portal Innovations.
Alnair Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alnair Therapeutics's valuation, stock price, and market status.
